Recherche
Résultats 1-8 de 8
-
Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma
American journal of hematology, 2016, 91, 179-184Article dans une revue scientifique -
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
Lancet (London, England), 2016, 387, 2402-2411Article dans une revue scientifique -
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
The Lancet. Oncology, 2015, 16, 704-715Article dans une revue scientifique -
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study
The Lancet. Haematology, 2015, 2, E160-E165Article dans une revue scientifique -
Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study
The Lancet. Haematology, 2018, 5, E403-E410Article dans une revue scientifique -
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma
British journal of haematology, 2016, 173, 722-730Article dans une revue scientifique -
FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study
Blood, 2017, 130, 1315-1326Article dans une revue scientifique -
Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA
Ann. Oncol., 2016, 27, 1349-1350Article dans une revue scientifique